PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 48/00 — A2

(11) International Publication Number: WO 00/25827

(43) International Publication Date: 11 May 2000 (11.05.00)

(21) International Application Number: PCT/EP99/07874

(22) International Filing Date: 18 October 1999 (18.10.99)

(30) Priority Data:
MI98A002330 30 October 1998 (30.10.98) IT

(71) Applicant *(for all designated States except US)*: MENARINI RICERCHE S.P.A. [IT/IT]; Via Tito Speri, 10, I-00040 Pomezia (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PARENTE, Dino [IT/IT]; (IT). DI MASSIMO, Anna, Maria [IT/IT]; (IT). DE SANTIS, Rita [IT/IT]; Via Risorgimento, I-50131 Firenze (FI).

(74) Agent: MINOIA, Fabrizio; Bianchetti Bracco Minoja Srl, Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: PHARMACEUTICAL COMPOSITION, CONTAINING FRAGMENTS OF AN ANTIGENIC PROTEIN ENCODING DNA ENDOWED WITH ANTI-TUMOR EFFECT

(57) Abstract

Provided herein is a pharmaceutical composition containing one or more DNA molecules encoding fragments of a protein overexpressed in tumor cells, in order to induce an anti-tumor Ag-specific immune response, in association with suitable excipients and adjuvants.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITION, CONTAINING FRAGMENTS OF AN ANTIGENIC PROTEIN ENCODING DNA ENDOWED WITH ANTI-TUMOR EFFECT.

Field of the invention

The invention relates to a pool of DNA plasmid constructs containing the sequences of human MUC-1 encoding fragments and to a pool of DNA plasmids in which the fragments themselves are preceded by the sequence encoding a protein consisting of human ubiquitin fused to a bacterial LacI fragment. The invention further relates to their use in the preparation of pharmaceutical compositions for use as DNA anti-tumor vaccines.

Background art

The invention provides an anti-tumor therapy based on the induction or activation of the immune response able to bring about tumor rejection. The validity of such an idea is demonstrated from the first clinical results; for example, patients treated with a viral vaccine containing the Carcinoembryonic Antigen (CEA) encoding sequences demonstrated immune system activation against this antigen (Tsang KY et al. J. Natl. Cancer. Inst. 87: 982, 1995).

The activation of an immune anti-tumor response is achievable through four different approaches:

a) *Ex vivo* engineering of patient tumor cells in order to make them more immunogenic and suitable as a vaccine;

b) *Ex vivo* engineering of patient immune cells in order to pre-activate an *in vitro* immune response.

c) Inoculation of naked or liposome capsulated or viral particle integrated (retrovirus, vaccinia virus, adenovirus, etc.) DNA encoding tumor associated antigens;

d) Treatment with recombinant or synthetic soluble tumor antigens conjugated or mixed with adjuvants.

The first two approaches consist of the engineering of every single patient cell and are limited in that they are necessarily patient-specific, while the latter two are aimed to

obtain products comparable to a traditional drug.

The new vaccination methods reflect the development of new technologies. The recent indications coming from the experimentation on DNA naked vaccines that induce either a persistent antibody or a cell immune response, make the traditional protein subunit vaccines constituted of certain specific peptides, inducing a lymphocyte population, obsolete. Intramuscularly or intradermically injected proteins, encoded by naked DNA, induce a cytotoxic-specific response as well as a helper response. This powerful combination is extremely effective but the underling mechanism is not completely clarified yet. Muscle cells express class I MHC antigens at low levels only, and do not apparently express class II antigens or co-stimulatory molecules. Consequently, transfected muscle cells are unlikely to play an important role in the onset of the immune response per se. Recent data show that Antigen Presenting Cells (APC), such as macrophages or dendritic cells, play a fundamental role in capturing the myocyte released antigen and in the subsequent processing and presenting of the respective peptides in the context of the class I and II molecules, thus inducing a CD8+ cell activation with cytotoxic activity as well as activation of the CD4+ cells co-operating with B lymphocytes in eliciting the antibody response (*Corr M et al J. Exp. Med. 184:1555, 1996*) (*Tighe, H. et al. Immunology Today 19:89, 1998*).

Furthermore, the use of cytokines is known to improve the therapeutic effect deriving from immunization with DNA. Cytokines can be administered in the form of exogenous proteins as reported in *Irvine et al., J. Immunol. 156: 238, 1996*. An alternative approach is represented by the contemporaneous inoculation of both the tumor antigen or the desired cytokine encoding plasmids, thus allowing the cytokine to be produced *in situ* (*Kim JJ et al. Immunol 158: 816, 1997*).

The active immunization approach of the present invention is based on the use of DNA vectors as vaccines against the MUC-1

human antigen or Polymorphic Epithelial Mucin (PEM), overexpressed in tumor cells. MUC-1 is an epithelial luminal surface glycoprotein (*Patton S. et al. BBA 1241:407, 1995*). In the cell transformation process this glycoprotein loses the apical localization and its expression level rises dramatically. The protein function consists of protecting the luminal surfaces, for example in the mammal gland, ovary, endometrium, colon, stomach, pancreas, bladder, kidney, etc. A glycosylation defect is reported that makes tumor cell associated MUC-1 antigenically different from normal cell associated MUC-1. This phenomenon causes tumor MUC-1 to expose the antigen epitopes that are normally masked by the sugar moieties in the normal cell expressed MUC-1. This characteristic makes tumor MUC-1 particularly interesting in an induction of a tumor specific antibody response (*Apostolopoulos V. et al. Crit. Rev. Immunol. 14:293, 1994*).

As an objective, the vaccination is aimed at inducing immune responses against tumor cells expressing MUC1 at high levels, preserving at the same time the low expressing normal epithelia. The DNA vaccination relies upon the entrance of a gene or portions thereof inside the body cells followed by transcription and translation of the inserted sequence and thus the intracellular synthesis of the corresponding polypeptide. An important advantage of this system is that the neo-synthesized protein is naturally processed inside the cell and the produced peptides are associated with the Major Histocompatibility Complex class I molecules (MHC-I). The MHC/peptide complexes are therefore naturally exported to the cell surface where they can be recognized by the immune system CD8+ cytotoxic cells. Only the polypeptides synthesized inside the cell are then processed and presented in association with the MHC class I molecules, thus making it the only mechanism to stimulate, a specific cytotoxic response. Vaccination systems based on protein or peptide administration are usually more effective in stimulating

the antibody immune response which, to date, has been shown to be ineffective in rejecting tumor cells. Current gene therapy techniques rely upon DNA packaging in recombinant viral vectors (retrovirus and adenovirus). The naked DNA administration is much more advantageous in terms of effectiveness and safety compared to viral vector therapies (*Kumar V and Sercarz E. Nature Med. 2: 857, 1996; McDonnel WM et al., New England J. of Med. 334: 42, 1996*). In fact naked DNA is unable either to duplicate or integrate in the host tissue DNA and does not induce the immune response to viral proteins.

The use of the ubiquitin to enhance the neo-synthesized protein processing and thus cytotoxic lymphocyte induction was recently reported (*Rodriguez F. et al., J. Virology 71: 8497, 1997*). The use of ubiquitin in order to generate proteins with an N-terminal amino acid, making them unstable and thus prone to enhanced degradation, had been previously reported (*Bechmair A. et al., SCIENCE 234: 179, 1986*). The higher instability of these proteins was subsequently related to enhanced intracellular processing and presentation of model proteins by MHC-1 (*Grant E P et al., J. Immunol. 155: 3750, 1995*) (*Wu Y and Kipps T.J., J. Immunol. 159: 6037, 1997*).

The use of single constructs containing partial antigen encoding DNA fragments (influenza virus nucleoprotein), having a higher antigenic presentation efficiency compared to the analogues with the whole antigenic sequence, in DNA vaccination was reported (*Anton L. C. et al., J. Immunol. 158: 2535, 1997*). Furthermore the processing of intracellular proteins and presentation of the respective peptides by MHC class I proteins in physiologic conditions, underlie the mechanism of immunological surveillance. For a given protein and a specific MHC context, there are peptide fragments termed dominants (i. e. prevailing on subdominants or cryptics), which are unable to generate any immune response because they are recognized as "self". It has now been outlined, according to an aspect of the

present invention, that an approach aimed at supporting the non-dominant epitope presentation by the administration of a mix of antigen protein fragments is able to elicit a surprising cytotoxic immune response.

Description of the invention

It has now been found that DNA molecules, encoding fragments of a protein overexpressed in tumor cells, can be conveniently used to induce an antigen-specific anti-tumor immune response.

The invention relates particularly to a pharmaceutical composition containing one or more DNA encoding Mucin (MUC-1) protein fragments.

The DNA used in the present invention can be plasmid or viral DNA, preferably plasmid DNA obtained employing the pMRS30 expression vector described in fig. 13.

The compositions according to the invention contain preferably at least two DNA fragments of the Mucin (MUC-1) or of another protein overexpressed in tumor cells.

The compositions according to the invention contain preferably at least four fragments, each ranging from 200 to about 700 nucleotides, each sequence being juxtaposed and possibly partially overlapping, from about 50 to about 150 nucleotides, at the 3' and/or 5' end of the adjacent one.

The DNA fragments according to the invention can be possibly preceded at the 5' end by a ubiquitin encoding DNA sequence and possibly also by a LacI portion of Escherichia coli.

The invention relates also to new DNA fragments and to the use of Mucin-1 fragments defined above in the medicine and anti-tumor vaccine preparation.

Description of the figures

Fig. 1

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS166 expression

vector. This DNA includes the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by the two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-339 fragment of the EMBL sequence J05581.

Fig. 2

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS169 expression vector. This DNA includes the sequence corresponding to nucleotides 205-720 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 205-720 fragment of the EMBL sequence J05581.

Fig. 3

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS168 expression vector. This DNA includes the sequence corresponding to nucleotides 631-1275 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 631-1275 fragment of the EMBL sequence J05581.

Fig. 4

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS167 expression vector. This DNA includes the sequence corresponding to nucleotides 1222-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the

amino acids encoded by the 1222-1497 fragment of the EMBL sequence J05581.

Fig. 5

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS175 expression vector. This DNA includes the sequence corresponding to nucleotides 136-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-1497 fragment of the EMBL sequence J05581.

Fig. 6

Nucleotide DNA sequence (with the respective amino acid sequence) termed UBILacI. The encoded polypeptide includes the Ubiquitin sequence fused to a partial sequence of the bacterial protein beta-galactosidase, as described in *Chau V. et al. Science 243: 1576, 1989.*

Fig. 7

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the expression vector pMRS30 to give the pMRS171 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The coded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-339 of the EMBL sequence J05581.

Fig. 8

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS174 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 205-720 of the EMBL

sequence J05581 followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 205-720 of the EMBL sequence J05581.

Fig. 9

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS173 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 631-1275 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 631-1275 of the EMBL sequence J05581.

Fig. 10

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS172 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 1222-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 1222-1497 of the EMBL sequence J05581.

Fig. 11

Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the XbaI site of the pMRS30 expression vector to give the pMRS176 expression vector. This DNA includes the sequence named UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 136-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and

TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-1497 of the EMBL sequence J05581.

Fig. 12

Electrophoretic analysis on 1% agarose gel in 1X TBE. mRNA extracted from CHO, CD34+ dendritic cells and dendritic cells from PBMC, respectively, transfected with pMRS169, and subjected to RT-PCR reaction either with (lanes 4, 8, 12) or without (lanes 5, 9, 13) Reverse Transcriptase. Molecular weight DNA marker (lane 1); internal negative controls (lanes 2, 6); internal positive controls (lanes 3, 7, 10, 11); positive control from Promega kit (lane 14).

Fig. 13

Nucleotide sequence of the pMRS30 expression vector. The 1-2862 region corresponds to the AccI (location 504) - BamHI (location 3369) region of the pSV2CAT vector (EMBL M77788); the 2863-3721 region includes the human cytomegalovirus promoter (human cytomegalovirus major immediate-early gene enhancer); the 3722-4905 region includes several cloning sites, including XbaI (location 3727), and the processing signal of the rabbit beta-globin gene.

Detailed description of the invention

A DNA plasmid pool encoding, in eukaryotic cells, fragments of the MUC-1 human protein antigen was prepared. Constructs are based on the mammalian expression vector termed pMRS30, described in figure 13 and previously claimed in the Patent Application WO95/11982, and contain partial sequences of the MUC-1 cDNAs reported in the EMBL database with accession number J05581. MUC-1 encoding DNA was fragmented so that each fragment represents a discrete portion, partially overlapping to the adjacent ones. Administration of a mix of such plasmids can cause different plasmids to transfect different APC cells at the administration site. Therefore such cells produce and process

discrete portions of the MUC-1 protein giving the related peptides. In those conditions, the occurring subdominant and cryptic peptides can also be presented in association with class I MHC molecules thus generating a cytotoxic immune response.

The present invention thus relates to the use of a group of four constructs (Figures 1 to 4) containing MUC-1 cDNA partial fragments in admixture containing at least two of them and a group of four constructs (Figures 7 to 10) containing MUC-1 cDNA partial fragment preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion (Figure 6) used separately or in admixture containing at least two of them.

The present invention relates also to the use of the construct (Figure 5) containing the almost complete sequence of the MUC-1 cDNA and the construct (Figure 11) containing the almost complete sequence of the MUC-1 cDNA preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion.

The mixture of the four constructs containing the partial fragments of the MUC-1 cDNA and the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA preceded by the DNA encoding a protein sequence, containing Ubiquitin and an Escherichia coli Lac I portion, represents a preferred embodiment of the present invention.

Constructs according to the present invention can be used in the anti-tumor therapy of patient affected with tumors characterized by high MUC-1 expression.

Constructs described in the present invention were obtained as follows.

In the case of the first series of constructs, the fragments of the MUC-1 DNA were obtained by RT-PCR from BT20 cell line or by DNA partial chemical synthesis. Such fragments were then cloned into the pMRS30 expression vector and verified by sequencing.

In the case of the second series of constructs, the fragments were obtained from the first series of constructs by a PCR re-amplification. These fragments were then fused to the DNA encoding the Ubiquitin (obtained by RT-PCR from MCF7 cell line mRNA) and a partial lacI sequence (obtained by PCR from the commercial vector pGEX). DNA sequences thus obtained were then cloned in the pMRS30 expression vector and verified by sequencing. For the intended therapeutic or prophylactic uses, fragments or constructs according to the invention are suitably formulated, using carriers and methods previously employed in naked DNA vaccines, as described for example in The Immunologist, 1994, 2:1; WO 90/11092, Proc. Natl. Acad. Sci. U.S.A., 1986, 83, 9551; US 5580859; Immunology today 19 (1998), 89-97); Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 11478-11482; Nat. Med. 3 (1997), 526-532; Vaccine 12 (1994), 1495-1498; DNA Cell. Biol. 12 (1993), 777-783. The dosages will be determined on the basis of clinical and pharmacological-toxicological trials. Generally speaking, they will be comprised between 0.005 µg/kg and 5 µg/kg of the fragment mix. The composition of the invention can also contain a cytokine or a cytokine encoding plasmid.

The invention will be further illustrated by means of the following examples.

Example 1. Plasmid pMRS166 construction.

BT20 tumor cells (ATCC HTB-19) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.

An aliquot of this RNA was subjected to RT-PCR (reverse transcriptase-polymerase chain reaction) reaction in the presence of the following synthetic oligonucleotides:

V11 (5 GATCTCTAGAATGACAGGTTCTGGTCATGCAAGC 3)

V4 (5 GATCTCTAGAAAGCTTATCAACCTGAAGCTGGTTCCGTGGC 3)

The produced DNA fragment, purified and digested with the restriction enzyme XbaI, was cloned into the pMRS30 expression

vector, containing the human cytomegalovirus promoter and the beta-globin polyadenylation signal as claimed in the Patent WO9511982. The resulting pMRS166 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 136-339 of the EMBL sequence J05581, and two stop codons, TGA and TAA.

This fragment is reported in fig. 1.

Example 2. Plasmid pMRS169 construction.

An aliquot of the RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides:

V12 (5 GATCTCTAGAATGGTGCCCAGCTCTACTGAGAAGAATGC 3)

V15 (5 GGCGGTGGAGCCCGGGGCTGGCTTGT 3)

The produced DNA fragment, purified and digested with the restriction enzymes SmaI and XbaI, was fused, by the SmaI restriction site, to a DNA fragment entirely synthetically constructed, and including a sequence partially corresponding to the nucleotides 457-720 of the EMBL sequence J05581 and two stop codons, TGA and TAA. The whole fragment was thus cloned in the XbaI site of the pMRS30 expression vector. The resulting pMRS169 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 205-720 of the EMBL sequence J05581, and two stop codons, TGA and TAA.

This fragment is reported in fig. 2.

Example 3. Plasmid pMRS168 construction.

An aliquot of the RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides:

V13 (5 GATCTCTAGAATGGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)

V8 (5 GATCTCTAGAAAGCTTATCACAAGGCAATGAGATAGACAATGGCC 3)

The produced DNA fragment, purified and digested with the restriction enzyme XbaI was cloned in the pMRS30 expression vector. The resulting pMRS168 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the

nucleotides 631-1275 of the EMBL sequence J05581, and two stop codons, TGA and TAA.

This fragment is reported in fig. 3.

Example 4. Plasmid pMRS167 construction.

An aliquot of the RNA obtained as reported in example 1 was subjected to RT-PCR reaction in the presence of the following synthetic oligonucleotides:

V14 (5 GATCTCTAGAATGCTGGTGCTGGTCTGTGTTCTGGTTGCGC 3)

V10 (5 GATCTCTAGAAAGCTTATCACAAGTTGGCAGAAGTGGCTGC 3)

The produced DNA fragment, purified and digested with the restriction enzyme XbaI was cloned in the pMRS30 expression vector. The resulting pMRS167 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 1222-1497 of the EMBL sequence J05581, and two stop codons, TGA and TAA.

This fragment is reported in fig. 4.

Example 5. Plasmid pMRS175 construction.

pMRS166, 169, 168, 167 plasmids were subjected to PCR reaction in the presence of the following nucleotide pairs:

V11 (see example 1)

V18 (5 AACCTGAAGCTGGTTCCGTGGC 3) for pMRS166

V19 (5 GTGCCCAGCTCTACTGAGAAGAATGC 3)

V20 (5 GCTGGGAATTGAGAATGGAGTGCTCTTGC 3) for pMRS169

V21 (5 GGCTCAGCTTCTACTCTGGTGCACAACGGC 3)

V22 (5 CAAGGCAATGAGATAGACAATGGCC 3) for pMRS168

V23 (5 CTGGTGCTGGTCTGTGTTCTGGTTGCG 3)

V10 (see example 4) for pMRS167

The four DNA fragments obtained in the respective PCR reactions were mixed in equimolar amounts and PCR reacted in the presence of the V11 and V10 oligonuclotides.

The produced DNA fragment, purified and digested with the XbaI restriction enzyme, was cloned in the pMRS30 expression vector. The resulting pMRS175 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to

the nucleotides 136-1497 of the EMBL sequence J05581 and two stop codons TGA and TAA.

This fragment is reported in fig. 5.

Example 6. Plasmid pMRS171 construction.

MCF7 tumor cells (ATCC HTB-22) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.

An aliquot of this RNA was subjected to RT-PCR in the presence of the following synthetic oligonucleotides:

UBIup (5GATCTCTAGAATGCAGATCTTCGTGAAGACCCTGACTGGT 3)

UBIdown

(5TCACCAGCGAGACGGGCAACAGCCATGCACCACTACCGTGCCTCCCACCTCTGAGACGGAGC ACCAGG 3)

The reaction produces a DNA fragment termed fragment 1.

DNA from pGEX11T (Pharmacia) was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:

LacIup (5CCTCCGTCTCAGAGGTGGGAGGCACGGTAGTGGTGCATGGCTGTTGCCC GTCTCGCTGGTGAAAAG 3)

LacIdown (5GATCGGATCCTCGGGAAACCTGTCGTGCCAGCTGC 3)

This reaction gives a DNA fragment termed fragment 2.

The 1 and 2 DNA fragments, obtained in the respective PCR reactions, were mixed in equimolar amounts and subjected to PCR reaction in presence of the UBIup and LacIdown oligonucleotides.

The produced DNA fragment, purified and digested with the restriction enzymes XbaI and BamHI, was cloned into the pUC18 commercial plasmid. The resulting pMRS156 vector contains a DNA fragment including the sequence encoding the ubiquitin fused to the sequence encoding a bacterial beta-galactosidase portion. This fragment, termed UBILacI, is reported in fig. 6.

Plasmid pMRS166 DNA was subjected to a PCR reaction in presence of the following synthetic oligonucleotides:

V3 (5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3)

V4 (see Example 1)

The produced DNA fragment, purified and digested with the

restriction enzymes XbaI and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS171 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-339 nucleotides of the EMBL sequence J05581 and two stop codons, TGA and TAA. This fragment is reported in fig. 7.

Example 7. Plasmid pMRS174 construction.

Plasmid pMRS169 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:

V5 (5GATCGGATCCGTGCCCAGCTCTACTGAGAAGAATGC 3)

V6(5GATCTCTAGAAAGCTTATCAGCTGGGAATTGAGAATGGAGTGCTCTTGC 3)

The produced DNA fragment, purified and digested with the restriction enzymes XbaI and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS174 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 205-720 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 8.

Example 8. Plasmid pMRS173 construction.

Plasmid pMRS168 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:

V7 (5GATCGGATCCGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)

V8 (see example 3)

The produced DNA fragment, purified and digested with the restriction enzymes XbaI and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS173 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 631-1275 nucleotides of the EMBL sequence

J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 9.

Example 9. Plasmid pMRS172 construction.

Plasmid pMRS167 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:

V9 (5 GATCGGATCCCTGGTGCTGGTCTGTGTTCTGGTTGCGC 3)

V10 (see example 4)

The produced DNA fragment, purified and digested with the restriction enzymes XbaI and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS172 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 1222-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 10.

Example 10. Plasmid pMRS176 construction.

Plasmid pMRS167 DNA was subjected PCR reaction in the presence of the following synthetic oligonucleotides:

V3 (see example 6)

V10 (see example 4)

The produced DNA fragment, purified and digested with the restriction enzymes XbaI and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS176 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 11.

Example 11. Eukaryotic cell transfection and testing for transcription.

CHO (Chinese Hamster Ovary) cells were cultured in alpha MEM supplemented with ribonucleotides and deoxyribonucleotides

at transfection time.

Dendritic cells were obtained from CD34+ hemopoietic precursors cultured in IMDM without serum, supplemented with GM-CSF, IL4, SCF, Flt3 and TNFalpha. After 7 days the obtained cell population was transfected.

Dendritic cells were obtained from monocytes isolated from PBMC (peripheral blood mononuclear cells), cultured in RPMI supplemented with FCS, GM-CSF, and IL-4. After 7 days the obtained cell population was transfected.

In each case, about one million cells were transfected with one of the plasmids reported in examples 1 to 10. Transfection was carried out using 3 µg of plasmid DNA and 4 µl of DMRIE (Gibco) by lipofection.

After 24 hours cells were harvested, washed with PBS and lysed in order to extract the mRNA.

A mRNA aliquot was subjected to RT-PCR reaction in the presence of the oligonucleotide pair specific for the transfected DNA plasmid.

This experiment was carried out for each plasmid reported in the examples 1 to 10, using the following oligonucleotide pairs: V11/V4 for pMRS166, V12/V6 for pMRS169, V13/V8 for pMRS168, V4/V10 for pMRS167, V4/V10 for pMRS175, UBIup/V4 for pMRS171, UBIup/V6 for pMRS174, UBIup/V8 for pMRS173, UBIup/V10 for pMRS172, V14/V10 for pMRS176.

As a representative example, figure 12 reports the electrophoretic analysis of the DNA fragments obtained by RT-PCR from the mRNA of the three cell populations, transfected with the pMRS169 plasmid. In this case the oligonucleotide pair V12/V6 was used.

Example 12. *In vivo* study results.

In the *in vivo* studies, the mixtures of the four fragments and the pMRS30 plasmid (vector without insert and thus used as a negative control) were used. In order to test the occurred immunization, an ELISA test was used to show the human mucin

specific antigens.

The *in vivo* studies were conducted using human MUC1 transgenic C57BL mice. As a consequence in these animals the MUC1 protein represents a self-protein. The employed vaccination schedule consists of 3 intradermic (dorsal portion, 50 micrograms DNA for each side) administrations (at days 0, 14, 28) of 100 micrograms plasmid DNA. At day 14 after the last administration, the animals were sacrificed and sera were tested for anti-human mucin antibodies.

The assayed fragment mixes, object of the present invention, stimulated a good immune response in the treated animals.

On the other hand, vaccination experiments with a 60-aminoacid peptide corresponding to the 20 aminoacids reported in fig. 2, from location 86 to location 105, repeated three times (this peptide is termed 3XTR), were also carried out.

The two vaccinations differ in the type of the elicited antibody response. The antibody titer results much more higher in the vaccination with 3XTR. Furthermore the noticed IgG subtypes are in favor of an essentially humoral (antibody) response in the case of vaccination with 3XTR, and of a cellular response (cytotoxic) in the case of vaccination with DNA. For anti-tumor therapy, a principally cytotoxic immune response is preferable. Because the experiments were carried out on transgenic mice, in whom the human mucin is "self", we can foresee a similar response in humans. This response could justify the use, as DNA vaccines, of the compounds of the present invention in the treatment of MUC1 overxpressing human tumors.

CLAIMS

1. Pharmaceutical composition containing one or more DNA molecules, encoding fragments of a protein overexpressed in tumor cells in order to induce an antitumor Ag-specific immune response, in combination with suitable excipients and adjuvants.

2. Pharmaceutical composition according to claim 1 wherein the overexpressed protein is MUC-1.

3. Pharmaceutical composition according to claim 1 or 2 containing at least two DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1).

4. Composition according to claim 3 containing at least three DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1).

5. Composition according to claim 4 containing at least four DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1).

6. Composition according to claims 3, 4 or 5 wherein the DNA sequences comprise about 200 to about 700 nucleotides, each sequence being contiguous and possibly partially overlapping, from about 50 to about 150 nucleotides at the 3' and/or 5' end, to the adjacent one.

7. Pharmaceutical composition according to any claim from 2 to 6 wherein the used mixture consists of, at least, two plasmid DNA molecules, each containing a DNA fragment selected from those whose sequences are described in figures 1, 2, 3, and 4.

8. Pharmaceutical composition according to claim 7 wherein the used mixture consists of the pool of plasmid DNA molecules, where each molecule contains a DNA fragment selected from those whose sequences are described in figures 1, 2, 3, and 4.

9. Pharmaceutical composition according to claim 1 or 2 wherein a plasmid DNA molecule containing the sequence described in figure 5 is used.

10. Pharmaceutical composition according to claims 7, 8, or 9

wherein the used plasmid DNA molecules derive from the fusion of the pMRS30 expression vector in Fig. 13 to each sequence described in figures 1, 2, 3, 4, 5.

11. Pharmaceutical composition according to claims 2 to 6 wherein the used sequences, corresponding to single fragments of the protein, are preceded in the 5' termini by the sequence described in Fig. 6 encoding the ubiquitin and a LacI portion from Escherichia Coli.

12. Pharmaceutical composition according to claim 11 wherein the mixture consists of one or more sequences deriving from joining the pMRS30 expression vector, described in Fig. 13, to a DNA sequence selected from those described in figures 7, 8, 9, and 10.

13. Pharmaceutical composition according to claim 11 wherein the mixture consists of the totality of the sequences deriving from joining the pMRS30 expression vector to a DNA sequence selected from those described in figures 7, 8, 9, and 10.

14. Pharmaceutical composition according to claim 11 wherein the mixture consists of a sequence deriving from joining the pMRS30 expression vector to the sequence described in figure 11.

15. Pharmaceutical composition according to any preceding claims, further containing a cytokine or a cytokine encoding plasmid.

16. A plasmid DNA molecule consisting of the pMRS30 expression vector joined to a DNA sequence, encoding a MUC-1 protein fragment and whose sequence is selected from the group of those described in figures 1, 2, 3, 4, and 5.

17. A DNA molecule encoding a protein MUC-1 fragment preceded in its 5' terminus by the sequence described in Fig. 6.

18. A DNA molecule according to claim 17 selected from those described in figures 7, 8, 9, 10, and 11.

19. A plasmid DNA molecule obtained by joining the pMRS expression vector to a DNA molecule selected from those of claim 17 or 18.

20. Use of DNA molecules of claims 16-19 in the preparation of a composition with anti-tumor effect.

Figure 1


1 ATGACAGGTTCTGGTCATGCAAGCTCTACCCCAGGTGGAGAAAAG
1 Met Thr Gly Ser Gly Gly His Ala Ser Ser Thr Pro Gly Gly Glu Lys
46 GAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCTACTGAG
16 Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu
91 AAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGCCACAGC
31 Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His Ser
136 CCCGGTTCAGGCTCCTCCACCACTCAGGGACAGGATGTCACTCTG
46 Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
181 GCCCCGGCCACGGAACCAGCTTCAGGTTGATAA
61 Ala Pro Ala Thr Glu Pro Ala Ser Gly ••••••

Figure 2

```
   1 ATGGTGCCCAGCTCTACTGAGAAGAATGCTGTGAGTATGACCAGC
   1 Met Val ProSer Ser Thr Gl uLysAsnAl aVal Ser Met Thr Ser
  46 AGCGTACTCTCCAGCCACAGCCCCGGTTCAGGCTCCTCCACCACT
  16 Ser Val LeuSer Ser Hi s Ser ProGl ySer Gl ySer Ser Thr Thr
  91 CAGGGACAGGATGTCACTCTGGCCCCGGCCACGGAACCAGCTTCA
  31 Gl nGl yGl nAspVal Thr LeuAl aProAl aThr Gl uProAl aSer
 136 GGTTCAGCTGCCACCTGGGGACAGGATGTCACCTCGGTCCCAGTC
  46 Gl ySer Al aAl aThr TrpGl yGl nAspVal Thr Ser Val ProVal
 181 ACCAGGCCAGCCCTGGGCTCCACCACCCCGCCAGCCCACGATGTC
  61 Thr ArgProAl aLeuGl ySer Thr Thr ProProAl aHi sAspVal
 226 ACCTCAGCCCCGGACAACAAGCCAGCCCCGGGAAGTACTGCTCCA
  76 Thr Ser Al aProAspAsnLysProAl aProGl ySer Thr Al aPro
 271 CCAGCACACGGTGTTACCTCGGCTCCGGATACCAGGCCGGCCCCA
  91 ProAl aHi sGl yVal Thr Ser Al aProAspThr ArgProAl aPro
 316 GGTAGTACCGCCCCTCCTGCCCATGGTGTCACATCTGCCCCGGAC
 106 Gl ySer Thr Al aProProAl aHi sGl yVal Thr Ser Al aProAsp
 361 AACAGGCCTGCATTGGGTAGTACAGCACCGCCAGTACACAACGTT
 121 AsnArgProAl aLeuGl ySer Thr Al aProProVal Hi sAsnVal
 406 ACTAGTGCCTCAGGCTCTGCTAGCGGCTCAGCTTCTACTCTGGTG
 136 Thr Ser Al aSer Gl ySer Al aSer Gl ySer Al aSer Thr LeuVal
 451 CACAACGGCACCTCTGCGCGCGCGACCACAACCCCAGCGAGCAAG
 151 Hi sAsnGl yThr Ser Al aArgAl aThr Thr Thr ProAl aSer Lys
 496 AGCACTCCATTCTCAATTCCCAGCTGATAA
 166 Ser Thr ProPheSer Il eProSer******
```

Figure 3


1 ATGGGCTCAGCTTCTACTCTGGTGCACAACGGCACCTCTGCCAGG
1 Met Gly Ser Ala Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg
46 GCTACCACAACCCCAGCCAGCAAGAGCACTCCATTCTCAATTCCC
16 Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro
91 AGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCATAGCACC
31 Ser His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His Ser Thr
136 AAGACTGATGCCAGTAGCACTCACCATAGCACGGTACCTCCTCTC
46 Lys Thr Asp Ala Ser Ser Thr His His Ser Thr Val Pro Pro Leu
181 ACCTCCTCCAATCACAGCACTTCTCCCCAGTTGTCTACTGGGGTC
61 Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu Ser Thr Gly Val
226 TCTTTCTTTTTCCTGTCTTTTCACATTTCAAACCTCCAGTTTAAT
76 Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn
271 TCCTCTCTGGAAGATCCCAGCACCGACTACTACCAAGAGCTGCAG
91 Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln
316 AGAGACATTTCTGAAATGTTTTTGCAGATTTATAAACAAGGGGGT
106 Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly Gly
361 TTTCTGGGCCTCTCCAATATTAAGTTCAGGCCAGGATCTGTGGTG
121 Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val
406 GTACAATTGACTCTGGCCTTCCGAGAAGGTACCATCAATGTCCAC
136 Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His
451 GACGTGGAGACACAGTTCAATCAGTATAAAACGGAAGCAGCCTCT
151 Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser
496 CGATATAACCTGACGATCTCAGACGTCAGCGTGAGTGATGTGCCA
166 Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro
541 TTTCCTTTCTCTGCCCAGTCTGGGGCTGGGGTGCCAGGCTGGGGC
181 Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly
586 ATCGCGCTGCTGGTGCTGGTCTGTGTTCTGGTTGCGCTGGCCATT
196 Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile
631 GTCTATCTCATTGCCTTGTGATAA
211 Val Tyr Leu Ile Ala Leu ••••••

Figure 4

```
   1 ATGCTGGTGCTGGTCTGTGTTCTGGTTGCGCTGGCCATTGTCTAT
   1▶MetLeuValLeuValCysValLeuValAlaLeuAlaIleValTyr
  46 CTCATTGCCTTGGCTGTCTGTCAGTGCCGCCGAAAGAACTACGGG
  16▶LeuIleAlaLeuAlaValCysGlnCysArgArgLysAsnTyrGly
  91 CAGCTGGACATCTTTCCAGCCCGGGATACCTACCATCCTATGAGC
  31▶GlnLeuAspIlePheProAlaArgAspThrTyrHisProMetSer
 136 GAGTACCCCACCTACCACACCCATGGGCGCTATGTGCCCCCTAGC
  46▶GluTyrProThrTyrHisThrHisGlyArgTyrValProProSer
 181 AGTACCGATCGTAGCCCCTATGAGAAGGTTTCTGCAGGTAATGGT
  61▶SerThrAspArgSerProTyrGluLysValSerAlaGlyAsnGly
 226 GGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCCACTTCT
  76▶GlySerSerLeuSerTyrThrAsnProAlaValAlaAlaThrSer
 271 GCCAACTTGTGATAA
  91▶AlaAsnLeu******
```

Figure 5

```
   1 ATGACAGGTTCTGGTCATGCAAGCTCTACCCCAGGTGGAGAAAAG
   1 Met Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly Leu Lys
  46 GAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCTACTGAG
  16 Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu
  91 AAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGCCACAGC
  31 Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His Ser
 136 CCCGGTTCAGGCTCCTCCACCACTCAGGGACAGGATGTCACTCTG
  46 Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu
 181 GCCCCGGCCACGGAACCAGCTTCAGGTTCAGCTGCCACCTGGGGA
  61 Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly
 226 CAGGATGTCACCTCGGTCCCAGTCACCAGGCCAGCCCTGGGCTCC
  76 Gln Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser
 271 ACCACCCCGCCAGCCCACGATGTCACCTCAGCCCCGGACAACAAG
  91 Thr Thr Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys
 316 CCAGCCCCGGGAAGTACCGCTCCACCAGCACACGGTGTTACCTCG
 106 Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala Ala His Gly Val Thr Ser
 361 GCTCCGGATACCAGGCCGGCCCCAGGTAGTACCGCCCCTCCTGCC
 121 Ala Pro Asp Thr Arg Pro Ala Ala Pro Gly Ser Thr Ala Pro Pro Ala
 406 CATGGTGTCACATCTGCCCCGGACAACAGGCCTGCATTGGGTAGT
 136 His Gly Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser
 451 ACAGCACCGCCAGTACACAACGTTACTAGTGCCTCAGGCTCTGCT
 151 Thr Ala Pro Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala
 496 AGCGGCTCAGCTTCTACTCTGGTGCACAACGGCACCTCTGCGCGC
 166 Ser Gly Ser Ala Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg
 541 GCGACCACAACCCCAGCGAGCAAGAGCACTCCATTCTCAATTCCC
 181 Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro
 586 AGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCATAGCACC
 196 Ser His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His Ser Thr
 631 AAGACTGATGCCAGTAGCACTCACCATAGCACGGTACCTCCTCTC
 211 Lys Thr Asp Ala Ser Ser Thr His His Ser Thr Val Pro Pro Leu
 676 ACCTCCTCCAATCACAGCACTTCTCCCCAGTTGTCTACTGGGGTC
 226 Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu Ser Thr Gly Val
 721 TCTTTCTTTTTCCTGTCTTTCACATTTCAAACCTCCAGTTTAAT
 241 Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn
 766 TCCTCTCTGGAAGATCCCAGCACCGACTACTACCAAGAGCTGCAG
 256 Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln
 811 AGAGACATTTCTGAAATGTTTTTGCAGATTTATAAACAAGGGGGT
 271 Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln Gly Gly
 856 TTTCTGGGCCTCTCCAATATTAAGTTCAGGCCAGGATCTGTGGTG
 286 Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val Val
```

(Continued)

Figure 5 (continued)

```
 901 GTACAATTGACTCTGGCCTTCCGAGAAGGTACCATCAATGTCCAC
 301 Val Gln LeuThr LeuAla PheArgGluGlyThr IleAsnVal His
 946 GACGTGGAGACACAGTTCAATCAGTATAAAACGGAAGCAGCCTCT
 316 AspVal GluThr GlnPheAsnGlnTyrLysThr GluAlaAlaSer
 991 CGATATAACCTGACGATCTCAGACGTCAGCGTGAGTGATGTGCCA
 331 ArgTyrAsnLeuThr IleSerAspVal Ser Val SerAspVal Pro
1036 TTTCCTTTCTCTGCCCAGTCTGGGGCTGGGGTGCCAGGCTGGGGC
 346 PheProPheSer AlaGlnSer GlyAlaGlyVal ProGlyTrpGly
1081 ATCGCGCTGCTGGTGCTGGTCTGTGTTCTGGTTGCGCTGGCCATT
 361 IleAlaLeuLeuVal LeuVal CysVal LeuVal AlaLeuAla Ile
1126 GTCTATCTCATTGCCTTGGCTGTCTGTCAGTGCCGCCGAAAGAAC
 376 Val TyrLeuIleAlaLeuAla Val CysGlnCysArgArgLysAsn
1171 TACGGGCAGCTGGACATCTTTCCAGCCCGGGATACCTACCATCCT
 391 TyrGlyGlnLeuAspIlePheProAlaArgAspThr TyrHisPro
1216 ATGAGCGAGTACCCCACCTACCACACCCATGGGCGCTATGTGCCC
 406 Met Ser GluTyrProThr TyrHis ThrHisGlyArgTyrVal Pro
1261 CCTAGCAGTACCGATCGTAGCCCCTATGAGAAGGTTTCTGCAGGT
 421 ProSer Ser ThrAspArgSer ProTyrGluLysVal Ser AlaGly
1306 AATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCC
 436 AsnGlyGlySer Ser LeuSer TyrThrAsnProAlaValAlaAla
1351 ACTTCTGCCAACTTGTGATAA
 451 Thr Ser AlaAsnLeu******
```

Figure 6

```
   1 ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1 Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu
  46 GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16 Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
  91 CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31 Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe
 136 GCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46 Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
 181 ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly
 226 GGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76 Gly Arg His Gly Ser Gly Ala Trp Leu Leu Pro Val Ser Leu Val
 271 AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91 Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr Ala Ser Pro
 316 CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106 Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln Val Ser
 361 CGAGGATCC
 121 Arg Gly Ser
```

Figure 7

```
   1  ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1▶Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu
  46  GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16▶Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
  91  CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31▶Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe
 136  GCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46▶Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
 181  ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61▶Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly
 226  GGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76▶Gly Arg His Gly Ser Gly Ala Trp Leu Leu Pro Val Ser Leu Val
 271  AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91▶Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr Ala Ser Pro
 316  CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106▶Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln Val Ser
 361  CGAGGATCCACAGGTTCTGGTCATGCAAGCTCTACCCCAGGTGGA
 121▶Arg Gly Ser Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly
 406  GAAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCT
 136▶Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
 451  ACTGAGAAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGC
 151▶Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser
 496  CACAGCCCCGGTTCAGGCTCCTCCACCACTCAGGGACAGGATGTC
 166▶His Ser Pro Gly Ser Gly Ser Ser Thr Thr Thr Gln Gly Gln Asp Val
 541  ACTCTGGCCCCGGCCACGGAACCAGCTTCAGGTTGATAA
 181▶Thr Leu Ala Pro Ala Thr Glu Pro Ala Ser Gly ******
```

Figure 8

```
   1 ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1 Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu
  46 GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16 Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
  91 CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31 Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe
 136 GCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46 Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
 181 ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly
 226 GGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76 Gly Arg His Gly Ser Gly Ala Thr Trp Leu Leu Pro Val Ser Leu Val
 271 AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91 Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr Ala Ser Pro
 316 CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106 Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln Val Ser
 361 CGAGGATCCGTGCCCAGCTCTACTGAGAAGAATGCTGTGAGTATG
 121 Arg Gly Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Val Ser Met
 406 ACCAGCAGCGTACTCTCCAGCCACAGCCCCGGTTCAGGCTCCTCC
 136 Thr Ser Ser Val Leu Ser Ser His Ser Pro Gly Ser Gly Ser Ser
 451 ACCACTCAGGGACAGGATGTCACTCTGGCCCCGGCCACGGAACCA
 151 Thr Thr Gln Gly Gln Asp Val Thr Leu Ala Pro Ala Thr Glu Pro
 496 GCTTCAGGTTCAGCTGCCACCTGGGGACAGGATGTCACCTCGGTC
 166 Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln Asp Val Thr Ser Val
 541 CCAGTCACCAGGCCAGCCCTGGGCTCCACCACCCCGCCAGCCCAC
 181 Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr Pro Pro Ala His
 586 GATGTCACCTCAGCCCCGGACAACAAGCCAGCCCCGGGAAGTACT
 196 Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro Gly Ser Thr
 631 GCTCCACCAGCACACGGTGTTACCTCGGCTCCGGATACCAGGCCG
 211 Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro
 676 GCCCCAGGTAGTACCGCCCCTCCTGCCCATGGTGTCACATCTGCC
 226 Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala
 721 CCGGACAACAGGCCTGCATTGGGTAGTACAGCACCGCCAGTACAC
 241 Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His
 766 AACGTTACTAGTGCCTCAGGCTCTGCTAGCGGCTCAGCTTCTACT
 256 Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr
 811 CTGGTGCACAACGGCACCTCTGCGCGCGCGACCACAACCCCAGCG
 271 Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala
 856 AGCAAGAGCACTCCATTCTCAATTCCCAGCTGATAA
 286 Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser ******
```

Figure 9

```
   1 ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1▶MetGlnIlePheValLysThrLeuThrGlyLysThrIleThrLeu
  46 GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16▶GluValGluProSerAspThrIleGluAsnValLysAlaLysIle
  91 CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31▶GlnAspLysGluGlyIleProProAspGlnGlnArgLeuIlePhe
 136 GCAGCCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46▶AlaGlyLysGlnLeuGluAspGlyArgThrLeuSerAspTyrAsn
 181 ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61▶IleGlnLysGluSerThrLeuHisLeuValLeuArgLeuArgGly
 226 GGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76▶GlyArgHisGlySerGlyAlaTrpLeuLeuProValSerLeuVal
 271 AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91▶LysArgLysThrThrLeuAlaProAsnThrGlnThrAlaSerPro
 316 CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106▶ArgAlaLeuAlaAspSerLeuMetGlnLeuAlaArgGlnValSer
 361 CGAGGATCCGGCTCAGCTTCTACTCTGGTGCACAACGGCACCTCT
 121▶ArgGlySerGlySerAlaSerThrLeuValHisAsnGlyThrSer
 406 GCCAGGGCTACCACAACCCCAGCCAGCAAGAGCACTCCATTCTCA
 136▶AlaArgAlaThrThrThrProAlaSerLysSerThrProPheSer
 451 ATTCCCAGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCAT
 151▶IleProSerHisHisSerAspThrProThrThrLeuAlaSerHis
 496 AGCACCAAGACTGATGCCAGTAGCACTCACCATAGCACGGTACCT
 166▶SerThrLysThrAspAlaSerSerThrHisHisSerThrValPro
 541 CCTCTCACCTCCTCCAATCACAGCACTTCTCCCCAGTTGTCTACT
 181▶ProLeuThrSerSerAsnHisSerThrSerProGlnLeuSerThr
 586 GGGGTCTCTTTCTTTTTCCTGTCTTTTCACATTTCAAACCTCCAG
 196▶GlyValSerPhePheLeuSerPheHisIleSerAsnLeuGln
 631 TTTAATTCCTCTCTGGAAGATCCCAGCACCGACTACTACCAAGAG
 211▶PheAsnSerSerLeuGluAspProSerThrAspTyrTyrGlnGlu
 676 CTGCAGAGAGACATTTCTGAAATGTTTTTGCAGATTTATAAACAA
 226▶LeuGlnArgAspIleSerGluMetPheLeuGlnIleTyrLysGln
 721 GGGGGTTTTCTGGGCCTCTCCAATATTAAGTTCAGGCCAGGATCT
 241▶GlyGlyPheLeuGlyLeuSerAsnIleLysPheArgProGlySer
 766 GTGGTGGTACAATTGACTCTGGCCTTCCGAGAAGGTACCATCAAT
 256▶ValValGlnLeuThrLeuAlaPheArgGluGlyThrIleAsn
 811 GTCCACGACGTGGAGACACAGTTCAATCAGTATAAAACGGAAGCA
 271▶ValHisAspValGluThrGlnPheAsnGlnTyrLysThrGluAla
 856 GCCTCTCGATATAACCTGACGATCTCAGACGTCAGCGTGAGTGAT
 286▶AlaSerArgTyrAsnLeuThrIleSerAspValSerValSerAsp
 901 GTGCCATTTCCTTTCTCTGCCCAGTCTGGGGCTGGGGTGCCAGGC
 301▶ValProPheProPheSerAlaGlnSerGlyAlaGlyValProGly
 946 TGGGGCATCGCGCTGCTGGTGCTGGTCTGTGTTCTGGTTGCGCTG
 316▶TrpGlyIleAlaLeuLeuValLeuValCysValLeuValAlaLeu
 991 GCCATTGTCTATCTCATTGCCTTGTGATAA
 331▶AlaIleValTyrLeuIleAlaLeu••••••
```

Figure 10

```
   1 ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1 Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu
  46 GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16 Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
  91 CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31 Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe
 136 GCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46 Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
 181 ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61 Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly
 226 CGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76 Gly Arg His Gly Ser Gly Ala Trp Leu Leu Pro Val Ser Leu Val
 271 AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91 Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr Ala Ser Pro
 316 CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106 Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln Val Ser
 361 CGAGGATCCCTGGTGCTGGTCTGTGTTCTGGTTGCGCTGGCCATT
 121 Arg Gly Ser Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile
 406 GTCTATCTCATTGCCTTGGCTGTCTGTCAGTGCCGCCGAAGAAC
 136 Val Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn
 451 TACGGGCAGCTGGACATCTTTCCAGCCGGGATACCTACCATCCT
 151 Tyr Gly Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro
 496 ATGAGCGAGTACCCCACCTACCACACCCATGGGCGCTATGTGCCC
 166 Met Ser Glu Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro
 541 CCTAGCAGTACCGATCGTAGCCCCTATGAGAAGGTTTCTGCAGGT
 181 Pro Ser Ser Thr Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly
 586 AATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTGGCAGCC
 196 Asn Gly Gly Ser Ser Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala
 631 ACTTCTGCCAACTTGTGATAA
 211 Thr Ser Ala Asn Leu*****
```

Figure 11

```
   1 ATGCAGATCTTCGTGAAGACCCTGACTGGTAAGACCATCACTCTC
   1 Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu
  46 GAAGTGGAGCCGAGTGACACCATTGAGAATGTCAAGGCAAAGATC
  16 Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
  91 CAAGACAAGGAAGGCATCCCTCCTGACCAGCAGAGGCTCATCTTT
  31 Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe
 136 GCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAAC
  46 Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn
 181 ATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGT
  61 Ile Glu Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly
 226 GGGAGGCACGGTAGTGGTGCATGGCTGTTGCCCGTCTCGCTGGTG
  76 Gly Arg His Gly Ser Gly Ala Thr Trp Leu Leu Pro Val Ser Leu Val
 271 AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCC
  91 Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr Ala Ser Pro
 316 CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCC
 106 Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln Val Ser
 361 CGAGGATCCACAGGTTCTGGTCATGCAAGCTCTACCCCAGGTGGA
 121 Arg Gly Ser Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly
 406 GAAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCT
 136 Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser
 451 ACTGAGAAGAATGCTGTGAGTATGACCAGCAGCGTACTCTCCAGC
 151 Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser
 496 CACAGCCCCGGTTCAGGCTCCTCCACCACTCAGGGACAGGATGTC
 166 His Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val
 541 ACTCTGGCCCCGGCCACGGAACCAGCTTCAGGTTCAGCTGCCACC
 181 Thr Leu Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr
 586 TGGGGACAGGATGTCACCTCGGTCCCAGTCACCAGGCCAGCCCTG
 196 Trp Gly Gln Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu
 631 GGCTCCACCACCCCGCCAGCCCACGATGTCACCTCAGCCCCGGAC
 211 Gly Ser Thr Thr Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp
 676 AACAAGCCAGCCCCGGGAAGTACCGCTCCACCAGCACACGGTGTT
 226 Asn Lys Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val
 721 ACCTCGGCTCCGGATACCAGGCCGGCCCCAGGTAGTACCGCCCCT
 241 Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro
 766 CCTGCCCATGGTGTCACATCTGCCCCGGACAACAGGCCTGCATTG
 256 Pro Ala His Gly Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu
 811 GGTAGTACAGCACCGCCAGTACACAACGTTACTAGTGCCTCAGGC
 271 Gly Ser Thr Ala Pro Pro Val His Asn Val Thr Ser Ala Ser Gly
 856 TCTGCTAGCGGCTCAGCTTCTACTCTGGTGCACAACGGCACCTCT
 286 Ser Ala Ser Gly Ser Ala Ser Thr Leu Val His Asn Gly Thr Ser
```

(Continued)

Figure 11 (continued)

```
 901 GCGCGCGCGACCACAACCCCAGCGAGCAAGAGCACTCCATTCTCA
 301 AlaArgAlaThrThrThrProAlaSerLysSerThrProPheSer
 946 ATTCCCAGCCACCACTCTGATACTCCTACCACCCTTGCCAGCCAT
 316 IleProSerHisHisSerAspThrProThrThrLeuAlaSerHis
 991 AGCACCAAGACTGATGCCAGTAGCACTCACCATAGCACGGTACCT
 331 SerThrLysThrAspAlaSerSerThrHisHisSerThrValPro
1036 CCTCTCACCTCCTCCAATCACAGCACTTCTCCCCAGTTGTCTACT
 346 ProLeuThrSerSerAsnHisSerThrSerProGlnLeuSerThr
1081 GGGGTCTCTTTCTTTTTCCTGTCTTTTCACATTTCAAACCTCCAG
 361 GlyValSerPhePhePheLeuSerPheHisIleSerAsnLeuGln
1126 TTTAATTCCTCTCTGGAAGATCCCAGCACCGACTACTACCAAGAG
 376 PheAsnSerSerLeuGluAspProSerThrAspTyrTyrGlnGlu
1171 CTGCAGAGAGACATTTCTGAAATGTTTTTGCAGATTTATAAACAA
 391 LeuGlnArgAspIleSerGluMetPheLeuGlnIleTyrLysGln
1216 GGGGGTTTTCTGGGCCTCTCCAATATTAAGTTCAGGCCAGGATCT
 406 GlyGlyPheLeuGlyLeuSerAsnIleLysPheArgProGlySer
1261 GTGGTGGTACAATTGACTCTGGCCTTCCGAGAAGGTACCATCAAT
 421 ValValValGlnLeuThrLeuAlaPheArgGluGlyThrIleAsn
1306 GTCCACGACGTGGAGACACAGTTCAATCAGTATAAAACGGAAGCA
 436 ValHisAspValGluThrGlnPheAsnGlnTyrLysThrGluAla
1351 GCCTCTCGATATAACCTGACGATCTCAGACGTCAGCGTGAGTGAT
 451 AlaSerArgTyrAsnLeuThrIleSerAspValSerValSerAsp
1396 GTGCCATTTCCTTTCTCTGCCCAGTCTGGGGCTGGGGTGCCAGGC
 466 ValProPheProPheSerAlaGlnSerGlyAlaGlyValProGly
1441 TGGGGCATCGCGCTGCTGGTGCTGGTCTGTGTTCTGGTTGCGCTG
 481 TrpGlyIleAlaLeuLeuValLeuValCysValLeuValAlaLeu
1486 GCCATTGTCTATCTCATTGCCTTGGCTGTCTGTCAGTGCCGCCGA
 496 AlaIleValTyrLeuIleAlaLeuAlaValCysGlnCysArgArg
1531 AAGAACTACGGGCAGCTGGACATCTTTCCAGCCCGGGATACCTAC
 511 LysAsnTyrGlyGlnLeuAspIlePheProAlaArgAspThrTyr
1576 CATCCTATGAGCGAGTACCCCACCTACCACACCCATGGGCGCTAT
 526 HisProMetSerGluTyrProThrTyrHisThrHisGlyArgTyr
1621 GTGCCCCCTAGCAGTACCGATCGTAGCCCCTATGAGAAGGTTTCT
 541 ValProProSerSerThrAspArgSerProTyrGluLysValSer
1666 GCAGGTAATGGTGGCAGCAGCCTCTCTTACACAAACCCAGCAGTG
 556 AlaGlyAsnGlyGlySerSerLeuSerTyrThrAsnProAlaVal
1711 GCAGCCACTTCTGCCAACTTGTGATAA
 571 AlaAlaThrSerAlaAsnLeu******
```


1 2 3 4 5 6 7 8 9 10 11 12 13 14

Figure 13

```
1    CCAGGAAGCTCCTCTGTGTCCTCATAAACCCTAACCTCCTCTACTTGAGA
51   GGACATTCCAATCATAGGCTGCCCATCCACCCTCTGTGTCCTCCTGTTAA
101  TTAGGTCACTTAACAAAAAGGAAATTGGGTAGGGGTTTTTCACAGACCGC
151  TTTCTAAGGGTAATTTTAAAATATCTGGGAAGTCCCTTCCACTGCTGTGT
201  TCCAGAAGTGTTGGTAAACAGCCCACAAATGTCAACAGCAGAAACATACA
251  AGCTGTCAGCTTTGCACAAGGGCCCAACACCCTGCTCATCAAGAAGCACT
301  GTGGTTGCTGTGTTAGTAATGTGCAAAACAGGAGGCACATTTTCCCCACC
351  TGTGTAGGTTCCAAAATATCTAGTGTTTTCATTTTTACTTGGATCAGGAA
401  CCCAGCACTCCACTGGATAAGCATTATCCTTATCCAAAACAGCCTTGTGG
451  TCAGTGTTCATCTGCTGACTGTCAACTGTAGCATTTTTTGGGGTTACAGT
501  TTGAGCAGGATATTTGGTCCTGTAGTTTGCTAACACACCCTGCAGCTCCA
551  AAGGTTCCCCACCAACAGCAAAAAAATGAAAATTTGACCCTTGAATGGGT
601  TTTCCAGCACCATTTTCATGAGTTTTTTGTGTCCCTGAATGCAAGTTTAA
651  CATAGCAGTTACCCCAATAACCTCAGTTTTAACAGTAACAGCTTCCCACA
701  TCAAAATATTTCCACAGGTTAAGTCCTCATTTAAATTAGGCAAAGGAATT
751  CTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTC
801  ATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGT
851  GCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATC
901  CGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG
951  AAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGC
1001 GGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAA
```

Figure 13

2151 TAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGC

2201 TCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTC

2251 TTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCG

2301 GGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA

2351 CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTC

2401 CCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA

2451 GGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAG

2501 TCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT

2551 CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTA

2601 CGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTT

2651 ATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATA

2701 CCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAA

2751 GCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTAT

2801 TTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCAT

2851 AGTTAAGCCAGTATACAATCAATTATTGGCCATTAGCCATATTATTCATTG

2901 GTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTAT

2951 CCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC

3001 ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT

3051 CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTA

3101 AATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAAT

3151 AATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC

3201 AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTG

3251 TATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCC

(Continued)

Figure 13 (Continued)

3301 CGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGC

3351 AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGG

3401 CAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAG

3451 TCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAAC

3501 GGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGC

3551 GGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA

3601 CCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAA

3651 GACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACG

3701 CGGATTCCCCGTGCCAAGAAAGCTTGTCTAGAACCCGGGAGAGCTCCTGA

3751 GAACTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTA

3801 TTGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTT

3851 AGAATGGGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTG

3901 TTTCTTTCACTTTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCT

3951 TTTCATTTTCTGTAACTTTTTCGTTAAACTTTAGCTTGCATTTGTAACGA

4001 ATTTTTAAATTCACTTTTGTTTATTTGTCAGATTGTAAGTACTTTCTCTA

4051 ATCACTTTTTTTTCAAGGCAATCAGGGTATATTATATTGTACTTCAGCAC

4101 AGTTTTAGAGAACAATTGTTATAATTAAATGATAAGGTAGAATATTTCTG

4151 CATATAAATTCTGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTA

4201 CATCCTGGTCATCATCCTGCCTTTCTCTTTATGGTTACAATGATATACAC

4251 TGTTTGAGATGAGGATAAAATACTCTGAGTCCAAACCGGGCCCCTCTGCT

4301 AACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCT

4351 GGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATTCACTCCTCAGGTGC

4401 AGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCAC

(Continued)

Figure 13 (Continued)

1051 AAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGAT

1101 CTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCC

1151 AATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTG

1201 TTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAAT

1251 GACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCAT

1301 GACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTG

1351 CGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCT

1401 TTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACC

1451 GGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTG

1501 CAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACT

1551 CTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGC

1601 AGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATA

1651 AATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGG

1701 CCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA

1751 GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCAC

1801 TGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG

1851 ATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCT

1901 TTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACT

1951 GAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTT

2001 TTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGC

2051 GGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA

2101 CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCG

(Continued)

Figure 13 (Continued)

4451 AAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCAT

4501 GAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCA

4551 TTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATAT

4601 GGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTT

4651 GGCAACATATGCCATATGCTGGCTGCCATGAACAAAGGTGGCTATAAAGA

4701 GGTCATCAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAG

4751 AAAAGCCTTGACTTGAGGTTAGATTTTTTTTTATATTTTGTTTTGTGTTAT

4801 TTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGA

4851 TTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTCTCTG

4901 GATCC

SEQUENCE LISTING

<110> MENARINI RICERCHE S.p.A.

<120> PHARMACEUTICAL COMPOSITION, CONTAINING FRAGMENTS OF AN ANTIGENIC PROTEIN ENCODING DNA ENDOWED WITH ANTI-TUMOR EFFECT

<130> 5653MEUR

<140>
<141>

<150> MI98A002330
<151> 1998-10-30

<160> 35

<170> PatentIn Ver. 2.1

<210> 1
<211> 213
<212> DNA
<213> human

<400> 1
atgacaggtt ctggtcatgc aagctctacc ccaggtggag aaaaggagac ttcggctacc 60
cagagaagtt cagtgcccag ctctactgag aagaatgctg tgagtatgac cagcagcgta 120
ctctccagcc acagccccgg ttcaggctcc tccaccactc agggacagga tgtcactctg 180
gccccggcca cggaaccagc ttcaggttga taa 213

<210> 2
<211> 525
<212> DNA
<213> human

<400> 2
atggtgccca gctctactga gaagaatgct gtgagtatga ccagcagcgt actctccagc 60
cacagccccg gttcaggctc ctccaccact cagggacagg atgtcactct ggccccggcc 120
acggaaccag cttcaggttc agctgccacc tggggacagg atgtcacctc ggtcccagtc 180
accaggccag ccctgggctc caccaccccg ccagcccacg atgtcacctc agccccggac 240
aacaagccag ccccgggaag tactgctcca ccagcacacg gtgttacctc ggctccggat 300
accaggccgg ccccaggtag taccgcccct cctgcccatg gtgtcacatc tgccccggac 360
aacaggcctg cattgggtag tacagcaccg ccagtacaca acgttactag tgcctcaggc 420
tctgctagcg gctcagcttc tactctggtg cacaacggca cctctgcgcg cgcgaccaca 480
accccagcga gcaagagcac tccattctca attccagct gataa 525

<210> 3
<211> 654
<212> DNA
<213> human

<400> 3
atgggctcag cttctacttt ggtgcacaac ggcacctctg ccagggctac cacaacccca 60
gccagcaaga gcactccatt ctcaatttcc agccaccact ctgatactcc taccaccctt 120
gccagccata gcaccaagac tgatgccagt agcactcacc atagcacggt acctcctctc 180
acctcctcca atcacagcac ttctcccccag ttgtctactg gggtctcttt ctttttcctg 240
tcttttcaca tttcaaacct ccagtttaat tcctctctgg aagatcccag caccgactac 300
taccaagagc tgcagagaga catttctgaa atgtttttgc agatttataa acaaggggct 360
tttctgggcc tctccaatat taagttcagg ccaggatctg tggtggtaca attgactctg 420
gccttccgag aaggtaccat caatgtccac gacgtggaga cacagttcaa tcagtataaa 480
acggaagcag cctctcgata taacctgacg atcttcagacg tcagcgtgag tgatgtgcca 540
tttcctttct ctgcccagtc tggggctggg gtgccaggct ggggcatcgc gctgctggtg 600
ctggtctgtg ttctggttgc gctggccatt gtctatctca ttgccttgtg ataa 654

<210> 4
<211> 285
<212> DNA
<213> human

<400> 4
atgctggtgc tggtctgtgt tctggttgcg ctggccattg tctatctcat tgccttggct 60
gtctgtcagt gccgccgaaa gaactacggg cagctggaca tctttccagc ccgggatacc 120
taccatccta tgagcgagta cccaacctac cacacccatg ggcgctatgt gccccctagc 180
agtaccgatc gtagccccta tgagaaggtt tctgcaggta atggtggcag cagcctctct 240
tacacaaacc cagcagtggc agccacttct gccaacttgt gataa 285

<210> 5
<211> 1371
<212> DNA
<213> human

<400> 5
atgacaggtt ctggtcatgc aagctctacc ccaggtggag aaaaggagac ttcggctacc 60
cagagaagtt cagtgcccag ctctactgag aagaatgctg tgagtatgac cagcagcgta 120
ctctccagcc acagccccgg ttcaggctcc tccaccactc agggacagga tgtcactctg 180
gccccggcca cggaaccagc ttcaggttca gctgccacct ggggacagga tgtcacctcg 240
gtcccagtca ccaggccagc cctgggctcc accaccccgc cagcccacga tgtcacctca 300
gccccggaca acaagccagc cccgggaagt accgctccac cagcacacgg tgttacctcg 360
gctcggata ccaggccggc cccaggtagt accgccccctc ctgcccatgg tgtcacatct 420
gccccggaca acaggcctgc attgggtagt acagcaccgc cagtacacaa cgttactagt 480
gcctcaggct ctgctagcgg ctcagcttct actctggtgc acaacggcac ctctgcgcgc 540

gcgaccacaa ccccagcgag caagagcact ccattctcaa ttcccagcca ccactctgat 600
actcctacca cccttgccag ccatagcacc aagactgatg ccagtagcac tcaccatagc 660
acggtacctc ctctcacctc ctccaatcac agcacttctc cccagttgtc tactgggggtc 720
tctttctttt tcctgtcttt tcacatttca aacctccagt ttaattcctc tctggaagat 780
cccagcaccg actactacca agagctgcag agagacattt ctgaaatgtt tttgcagatt 840
tataaacaag ggggttttct gggcctctcc aatattaagt tcaggccagg atctgtggtg 900
gtacaattga ctctggcctt ccgagaaggt accatcaatg tccacgacgt ggagacacag 960
ttcaatcagt ataaaacgga agcagcctct cgatataacc tgacgatctc agacgtcagc 1020
gtgagtgatg tgccatttcc tttctctgcc cagtctgggg ctgggggtgcc aggctggggc 1080
atcgcgctgc tggtgctggt ctgtgtttctg gttgcgctgg ccattgtcta tctcattgcc 1140
ttggctgtct gtcagtgccg ccgaaagaac tacgggcagc tggacatctt tccagcccgg 1200
gatacctacc atcctatgag cgagtacccc acctaccaca cccatgggcg ctatgtgccc 1260
cctagcagta ccgatcgtag ccctatgag aaggtttctg caggtaatgg tggcagcagc 1320
ctctcttaca caaacccagc agtggcagcc acttctgcca acttgtgata a 1371

<210> 6
<211> 369
<212> DNA
<213> human

<400> 6
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgcccgt ctcgctggtg aaaagaaaaa ccaccctggc gcccaatacg 300
caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatcc 369

<210> 7
<211> 579
<212> DNA
<213> human

<400> 7
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgcccgt ctcgctggtg aaaagaaaaa ccaccctggc gcccaatacg 300
caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatcca caggttctgg tcatgcaagc tctaccccag gtggagaaaa ggagacttcg 420
gctacccaga gaagttcagt gcccagctct actgagaaga atgctgtgag tatgaccagc 480
agcgtactct ccagccacag ccccggttca ggctcctcca ccactcaggg acaggatgtc 540
actctggccc cggccacgga accagcttca ggttgataa 579

<210> 8
<211> 891
<212> DNA
<213> human

<400> 8
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgcccgt ctcgctggtg aaaagaaaaa ccaccctggc gcccaatacg 300
caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatccg tgcccagctc tactgagaag aatgctgtga gtatgaccag cagcgtactc 420
tccagccaca gccccggttc aggctcctcc accactcagg gacaggatgt cactctggcc 480
ccggccacgg aaccagcttc aggttcagct gccacctggg gacaggatgt cacctcggtc 540
ccagtcacca ggccagccct gggctccacc acccgccag cccacgatgt cacctcagcc 600
ccggacaaca agccagcccc gggaagtact gctccaccag cacacggtgt tacctcggct 660
ccggatacca ggccggccac aggtagtacc gccctcctg cccatggtgt cacatctgcc 720
ccggacaaca ggcctgcatt gggtagtaca gcaccgccag tacacaacgt tactagtgcc 780
tcaggctctg ctagcggctc agcttctact ctggtgcaca acggcacctc tgcgcgcgcg 840
accacaaccc cagcgagcaa gagcactcca ttctcaattc ccagctgata a 891

<210> 9
<211> 1020
<212> DNA
<213> human

<400> 9
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgccgt ctcgctggtg aaaagaaaaa ccaccctggc gcccaatacg 300
caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatccg gctcagcttc tactctggtg cacaacggca cctctgccag ggctaccaca 420
accccagcca gcaagagcac tccattctca attcccagcc accactctga tactcctacc 480
acccttgcca gccatagcac caagactgat gccagtagca ctcaccatag cacggtacct 540
cctctcacct cctccaatca cagcacttct ccccagttgt ctactggggt ctctttcttt 600
ttcctgtctt ttcacatttc aaacctccag tttaattcct ctctggaaga tcccagcacc 660
gactactacc aagagctgca gagagacatt tctgaaatgt ttttgcagat ttataaacaa 720
ggggggtttc tgggcctctc caatattaag ttcaggccag gatctgtggt ggtacaattg 780
actctggcct tccgagaagg taccatcaat gtccacgacg tggagacaca gttcaatcag 840
tataaaacgg aagcagcctc tcgatataac ctgacgatct cagacgtcag cgtgagtgat 900
gtgccatttc ctttctctgc ccagtctggg gctggggtgc caggctgggg catcgcgctg 960
ctggtgctgg tctgtgttct ggttgcgctg gccattgtct atctcattgc cttgtgataa 1020

<210> 10
<211> 651
<212> DNA
<213> human

<400> 10
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgcccgt ctcgctggtg aaaagaaaaa ccacccctggc gcccaatacg 300
caaacgcct ctcccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatccc tggtgctggt ctgtgtttctg gttgcgctgg ccattgtcta tctcattgcc 420
ttggctgtct gtcagtgccg ccgaaagaac tacgggcagc tggacatctt tccagcccgg 480
gatacctacc atcctatgag cgagtacccc acctaccaca cccatgggcg ctatgtgccc 540
cctagcagta ccgatcgtag cccctatgag aaggtttctg caggtaatgg tggcagcagc 600
ctctcttaca caaacccagc agtggcagcc acttctgcca acttgtgata a 651

<210> 11
<211> 1737
<212> DNA
<213> human

<400> 11
atgcagatct tcgtgaagac cctgactggt aagaccatca ctctcgaagt ggagccgagt 60
gacaccattg agaatgtcaa ggcaaagatc caagacaagg aaggcatccc tcctgaccag 120
cagaggctca tctttgcagg caagcagctg gaagatggcc gcactctttc tgactacaac 180
atccagaaag agtccaccct gcacctggtg ctccgtctca gaggtgggag gcacggtagt 240
ggtgcatggc tgttgcccgt ctcgctggtg aaaagaaaaa ccacccctggc gcccaatacg 300
caaacgcct ctcccgcgc gttggccgat tcattaatgc agctggcacg acaggtttcc 360
cgaggatcca caggtttctgg tcatgcaagc tctacccccag gtggagaaaa ggagacttcg 420
gctacccaga gaagttcagt gcccagctct actgagaaga atgctgtgag tatgaccagc 480
agcgtactct ccagccacag ccccggttca ggctcctcca ccactcaggg acaggatgtc 540
actctggccc cggccacgga accagcttca ggttcagctg ccacctgggg acaggatgtc 600
acctcggtcc cagtcaccag gccagcccctg ggctccacca ccccgccagc ccacgatgtc 660
acctcagccc cggacacaaa gccagcccag ggaagtaccg ctccaccagc acacggtgtt 720
acctcggctc cggataccag gccggcccca ggtagtaccg cccctcctgc ccatggtgtc 780
acatctgccc cggacaacag gcctgcattg ggtagtacag caccgccagt acacaacgtt 840
actagtgcct caggctctgc tagcggctca gcttctactc tggtgcacaa cggcacctct 900
gcgcgcgcga ccacaacccc agcgagcaag agcactccat tctcaattcc cagccaccac 960
tctgatactc ctaccaccct tgccagccat agcaccaaga ctgatgccag tagcactcac 1020
catagcacgg taacctcctct cacctcctcc aatcacagca cttctcccca gttgtctact 1080
ggggtctctt tcttttttct gtcttttcac atttcaaacc tccagtttaa ttcctctctg 1140
gaagatccca gcaccgacta ctaccaagag ctgcagagag acatttctga aatgtttttg 1200
cagatttata aacaaggggg ttttctgggc ctctccaata ttaagttcag gccaggatct 1260
gtggtggtac aattgactct ggccttccga gaaggtacca tcaatgtcca cgacgtggag 1320

acacagttca atcagtataa aacggaagca gcctctcgat ataacctgac gatctcagac 1380
gtcagcgtga gtgatgtgcc atttcctttc tctgcccagt ctggggctgg ggtgccaggc 1440
tggggcatcg cgctgctggt gctggtctgt gttctggttg cgctggccat tgtctatctc 1500
attgccttgg ctgtctgtca gtgccgccga aagaactacg ggcagctgga catctttcca 1560
gccgggata cctaccatcc tatgagcgag taccccacct accacaccca tgggcgctat 1620
gtgcccccta gcagtaccga tcgtagcccc tatgagaagg tttctgcagg taatggtggc 1680
agcagcctct cttacacaaa cccagcagtg gcagccactt ctgccaactt gtgataa 1737

<210> 12
<211> 4905
<212> DNA
<213> human

<400> 12
ccaggaagct cctctgtgtc ctcataaacc ctaacctcct ctacttgaga ggacattcca 60
atcataggct gcccatccac cctctgtgtc ctcctgttaa ttaggtcact taacaaaaag 120
gaaattgggt agggggtttt cacagaccgc tttctaaggg taattttaaa atatctggga 180
agtccctcc actgctgtgt tccagaagtg ttggtaaaca gcccacaaat gtcaacagca 240
gaaacataca agctgtcagc tttgcacaag ggcccaacac cctgctcatc aagaagcact 300
gtggttgctg tgttagtaat gtgcaaaaca ggaggcacat tttccccacc tgtgtaggtt 360
ccaaaatatc tagtgttttc atttttactt ggatcaggaa cccagcactc cactggataa 420
gcattatcct tatccaaaac agccttgtgg tcagtgttca tctgctgact gtcaactgta 480
gcatttttg gggttacagt ttgagcagga tatttggtcc tgtagtttgc taacacaccc 540
tgcagctcca aaggttcccc accaacagca aaaaaatgaa aatttgaccc ttgaatgggt 600
tttcagcac cattttcatg agtttttgt gtcctgaat gcaagtttaa catagcagtt 660
accccaataa cctcagtttt aacagtaaca gcttcccaca tcaaaatatt tccacaggtt 720
aagtcctcat ttaaattagg caaaggaatt cttgaagacg aaagggcctc gtgatacgcc 780
tattttata ggttaatgtc atgataataa tggtttctta gacgtcaggt ggcacttttc 840
ggggaaatgt gcgcggaacc cctatttgtt tatttttcta aatacattca aatatgtatc 900
cgctcatgag acaataaccc tgataaatgc ttcaataata ttgaaaaagg aagagtatga 960
gtattcaaca tttccgtgtc gcccttattc ccttttttgc ggcatttttgc cttcctgttt 1020
ttgctcaccc agaaacgctg gtgaaagtaa aagatgctga agatcagttg ggtgcacgag 1080
tgggttacat cgaactggat ctcaacagcg gtaagatcct tgagagtttt cgccccgaag 1140
aacgttttcc aatgatgagc acttttaaag ttctgctatg tggcgcggta ttatcccgtg 1200
ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat gacttggttg 1260
agtactcacc agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca 1320
gtgctgccat aaccatgagt gataacactg cggccaactt acttctgaca acgatcggag 1380
gaccgaagga gctaaccgct tttttgcaca acatgggggga tcatgtaact cgccttgatc 1440
gttgggaacc ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg 1500
cagcaatggc aacaacgttg cgcaaactat taactggcga actacttact ctagcttccc 1560
ggcaacaatt aatagactgg atggaggcgg ataaagttgc aggaccactt ctgcgctcgg 1620
ccctttcggc tggctggttt attgctgata aatctggagc cggtgagcgt gggtctcgcg 1680
gtatcattgc agcactgggg ccagatggta agccctcccg tatcgtagtt atctacacga 1740
cggggagtca ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac 1800
tgattaagca ttggtaactg tcagaccaag tttactcata tatactttag attgatttaa 1860
aacttcattt ttaatttaaa aggatctagg tgaagatcct ttttgataat ctcatgacca 1920
aaatcccttа acgtgagttt tcgttccact gagcgtcaga ccccgtagaa aagatcaaag 1980

gatcttcttg agatcctttt tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac 2040
cgctaccagc ggtggtttgt ttgccggatc aagagctacc aactcttttt ccgaaggtaa 2100
ctggcttcag cagagcgcag ataccaaata ctgtccttct agtgtagccg tagttaggcc 2160
accacttcaa gaactctgta gcaccgccta catacctcgc tctgctaatc ctgttaccag 2220
tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt ggactcaaga cgatagttac 2280
cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc agcttggagc 2340
gaacgaccta cacgaactg agatacctac agcgtgagct atgagaaagc gccacgcttc 2400
ccgaagggag aaaggcggac aggtatccgg taagcggcag ggtcggaaca ggagagcgca 2460
cgagggagct tccagggggа aacgcctggt atctttatag tcctgtcggg tttcgccacc 2520
tctgacttga gcgtcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg 2580
ccagcaacgc ggcctttttа cggttcctgg ccttttgctg gccttttgct cacatgttct 2640
ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata 2700
ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 2760
gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc atatggtgca 2820
ctctcagtac aatctgctct gatgccgcat agttaagcca gtatacaatc aatattggcc 2880
attagccata ttattcattg gttatatagc ataaatcaat attggctatt ggccattgca 2940
tacgttgtat ccatatcata atatgtacat ttatattggc tcatgtccaa cattaccgcc 3000
atgttgacat tgattattga ctagttatta atagtaatca attacggggt cattagttca 3060
tagccoatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc 3120
gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat 3180
agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt 3240
acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc 3300
cgcctggcat tatgcccagt acatgaccтt atgggacttt cctacttggc agtacatcta 3360
cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg 3420
atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt 3480
gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg ccccattgac 3540
gcaaatgggc ggtaggcgtg tacggtggga ggtctatata agcagagctc gtttagtgaa 3600
ccgtcagatc gcctggagac gccatccacg ctgttttgac ctccatagaa gacaccgggа 3660
ccgatccagc ctccgcggcc gggaacggtg cattggaacg cggattcccc gtgccaagaa 3720
agcttgtcta gaacccggga gagctcctga gaacttcagg gtgagtttgg ggacccttga 3780
ttgttctttc tttttcgcta ttgtaaaatt catgttatat ggaggggggca aagtttttcag 3840
ggtgttgttt agaatgggaa gatgtcccтt gtatcaccat ggaccctcat gataattttg 3900
tttctttcac tttctactct gttgacaacc attgtctcct cttatttttct tttcatttta 3960
tgtaactttt tcgttaaact ttagcttgca tttgtaacga atttttaaat tcacttttgt 4020
ttatttgtca gattgtaagt actttctcta atcacttttt tttcaaggca atcagggtat 4080
attatattgt acttcagcac agttttagag aacaattgtt ataattaaat gataaggtag 4140
aatatttctg catataaatt ctggctggcg tggaaatatt cttattggta gaaacaacta 4200
catcctggtc atcatcctgc ctttctcttt atggttacaa tgatatacac tgtttgagat 4260
gaggataaaa tactctgagt ccaaacoggg cccctctgct aaccatgttc atgccttctt 4320
ctttttccta cagctcctgg gcaacgtgct ggttgttgtg ctgtctcatc attttggcaa 4380
agaattcact ccttcaggtgc aggctgccta tcagaaggtg gtggctggtg tggccaatgc 4440
cctggctcac aaatacccact gagatctttt tccctctgcc aaaaattatg gggacatcat 4500
gaagcccctt gagcatctga cttctggcta ataaaggaaa tttattttca ttgcaatagt 4560
gtgttggaat tttttgtgtc tctcactcgg aaggacatat gggagggcaa atcatttaaa 4620
acatcagaat gagtatttgg tttagagttt ggcaacatat gccatatgct ggctgccatg 4680
aacaaaggtg gctataaaga ggtcatcagt atatgaaaca gccccctgct gtccattcct 4740
tattccatag aaaagccttg acttgaggtt agattttttt tatattttgt ttttgtgttat 4800
ttttttcttt aacatcccta aaattttcct tacatgtttt actagccaga tttttcctcc 4860

tctcctgact actcccagtc atagctgtcc ctcttctctg gatcc 4905

<210> 13
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 13
gatcggatcc acaggttctg gtcatgcaag c 31

<210> 14
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 14
gatctctaga aagcttatca acctgaagct ggttccgtgg c 41

<210> 15
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 15
gatcggatcc gtgcccagct ctactgagaa gaatgc 36

<210> 16
<211> 49
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 16
gatctctaga aagcttatca gctgggaatt gagaatggag tgctcttgc 49

<210> 17
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 17
gatcggatcc ggctcagctt ctactctggt gcacaacggc 40

<210> 18
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 18
gatctctaga aagcttatca caaggcaatg agatagacaa tggcc 45

<210> 19
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 19
gatcggatcc ctggtgctgg tctgtgttct ggttgcgc 38

<210> 20
<211> 41

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 20
gatctctaga aagcttatca caagttggca gaagtggctg c 41

<210> 21
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 21
gatctctaga atgacaggtt ctggtcatgc aagc 34

<210> 22
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 22
gatctctaga atggtgccca gctctactga gaagaatgc 39

<210> 23
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 23
gatctctaga atgggctcag cttctactct ggtgcacaac ggc 43

<210> 24
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 24
gatctctaga atgctggtgc tggtctgtgt tctggttgcg c 41

<210> 25
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 25
ggcggtggag cccggggctg gcttgt 26

<210> 26
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 26
aacctgaagc tggttccgtg gc 22

<210> 27
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

oligonucleotide

<400> 27
gtgcccagct ctactgagaa gaatgc 26

<210> 28
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 28
gctgggaatt gagaatggag tgctcttgc 29

<210> 29
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 29
ggctcagctt ctactctggt gcacaacggc 30

<210> 30
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 30
caaggcaatg agatagacaa tggcc 25

<210> 31
<211> 27
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 31
ctggtgctgg tctgtgttct ggttgcg 27

<210> 32
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 32
gatctctaga atgcagatct tcgtgaagac cctgactggt 40

<210> 33
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 33
tcaccagcga gacgggcaac agccatgcac cactaccgtg cctcccacct ctgagacgga 60
gcaccagg 68

<210> 34
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 34
cctccgtctc agaggtggga ggcacggtag tggtgcatgg ctgttgccag tctcgctggt 60

gaaaag 66

<210> 35
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic oligonucleotide

<400> 35
gatcggatcc tcgggaaacc tgtcgtgcca gctgc 35